Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics
PPD
APRIL 14, 2025
Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate. However, it is representative of the average across most of todays trials, where only 2030% of participants are women. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.
Let's personalize your content